646 related articles for article (PubMed ID: 19755624)
1. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
Tan EH; Chan A
Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
[TBL] [Abstract][Full Text] [Related]
2. Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.
Boucher J; Olson L; Piperdi B
Clin J Oncol Nurs; 2011 Oct; 15(5):501-8. PubMed ID: 21951736
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous reactions to epidermal growth factor receptor inhibitors.
Pomerantz RG; Mirvish ED; Geskin LJ
J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
6. Clinical management of EGFRI dermatologic toxicities: US perspective.
Lacouture ME; Cotliar J; Mitchell EP
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):17-21. PubMed ID: 18154214
[TBL] [Abstract][Full Text] [Related]
7. Clinical management of EGFRI dermatologic toxicities: the European perspective.
Segaert S; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):22-6. PubMed ID: 18159647
[TBL] [Abstract][Full Text] [Related]
8. Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective.
Iacovelli L
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):31-3. PubMed ID: 18154216
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
[TBL] [Abstract][Full Text] [Related]
10. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
Reck M; Gutzmer R
Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065
[TBL] [Abstract][Full Text] [Related]
11. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
12. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
13. Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment.
White KJ; Roydhouse JK; Scott K
Clin J Oncol Nurs; 2011 Feb; 15(1):88-96. PubMed ID: 21278044
[TBL] [Abstract][Full Text] [Related]
14. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors.
Sinclair R
Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():11-7. PubMed ID: 24512509
[TBL] [Abstract][Full Text] [Related]
15. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
Hassel JC; Kripp M; Al-Batran S; Hofheinz RD
Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799
[TBL] [Abstract][Full Text] [Related]
16. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches.
Nikolaou V; Stratigos A; Antoniou C; Kiagia M; Nikolaou C; Katsambas A; Syrigos K
Dermatology; 2010; 220(3):243-8. PubMed ID: 20110632
[TBL] [Abstract][Full Text] [Related]
17. Toward evidence-based management of the dermatologic effects of EGFR inhibitors.
LoRusso P
Oncology (Williston Park); 2009 Feb; 23(2):186-94. PubMed ID: 19323301
[TBL] [Abstract][Full Text] [Related]
18. Clinical management of EGFRI dermatologic toxicities: the Japanese perspective.
Yamazaki N; Muro K
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):27-8. PubMed ID: 18159648
[TBL] [Abstract][Full Text] [Related]
19. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.
Eilers RE; Gandhi M; Patel JD; Mulcahy MF; Agulnik M; Hensing T; Lacouture ME
J Natl Cancer Inst; 2010 Jan; 102(1):47-53. PubMed ID: 20007525
[TBL] [Abstract][Full Text] [Related]
20. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy.
Fox LP
J Am Acad Dermatol; 2007 Mar; 56(3):460-5. PubMed ID: 17147969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]